Matheis Dennis 4

What Happened
Dennis Matheis, a director of Lucid Diagnostics, reported an open-market purchase of 245,000 shares on 2026-05-20. The filing shows a weighted average purchase price of $1.00 per share for a total reported value of $245,270. This was a straight purchase (transaction code P), not an option exercise or award.

Key Details

• Transaction date: 2026-05-20; Form 4 filed 2026-05-21 (appears timely).
• Reported quantity and price: 245,000 shares at a weighted average price of $1.00; total $245,270.
• Price range disclosure (footnote): purchases occurred at prices between $0.9375 and $1.0200; the filer can provide a per-trade breakdown on request.
• Shares owned after transaction: not disclosed in the provided excerpt of the filing.
• Transaction type: Open-market purchase (code P). No 10b5-1 plan, tax withholding, or gift noted in the provided details.

Context
Open-market purchases by directors can be interpreted by some investors as a sign of confidence, but they are only one data point and do not guarantee future performance. This transaction was a direct buy of common stock rather than an exercise, grant, or other derivative action. For full ownership totals or a per-trade price breakdown, consult the complete Form 4 (Accession 0001094891-26-000217) or request the detailed trade breakdown referenced in the footnote.